+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Uncomplicated Urinary Tract Infection - Epidemiology Forecast - 2032

  • PDF Icon

    Drug Pipelines

  • 74 Pages
  • February 2022
  • Region: Global
  • DelveInsight
  • ID: 5357286
UP TO OFF until Dec 31st 2024
This Uncomplicated Urinary Tract Infection - Epidemiology Forecast-2032 report delivers an in-depth understanding of the Uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Uncomplicated Urinary Tract Infection trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Uncomplicated Urinary Tract Infection Understanding


The Uncomplicated Urinary Tract Infection epidemiology report gives a thorough understanding of Uncomplicated Urinary Tract Infection by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Urinary tract infection (UTI) is the most common bacterial infection caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. A UTI can develop in any part of the urinary tract, including the urethra, bladder, ureters, or kidneys. They are classified as either complicated or uncomplicated. Uncomplicated UTI (uUTI) typically affect individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. Complicated UTI is associated with factors that compromise the urinary tract or host defense. Infection in men, children, and pregnant women are considered complicated, as most of these cases involve some urologic abnormality. Other characteristics that denote a complicated infection include immunosuppressive conditions, diabetes, catheterization, renal transplantation, and neurogenic bladder. Consequently, uUTI occur in otherwise healthy, adult, non-pregnant females.

Symptoms of uUTI vary depending on the extent of the infection. Lower UTIs mainly involve the urethra, bladder, and tend to present with localized symptoms such as strong and frequent urge to urinate, cloudy, bloody, or strong-smelling urine, pain or a burning sensation when urinating. uUTI extending to the ureter or kidneys (i.e., pyelonephritis) often involves more systemic signs and symptoms, such as leukocytosis, fever, chills, abdominal pain, flank pain, and nausea/vomiting.

Diagnosis


The gold standard for UTI diagnosis is the urine examination, including quantitative urine culture and its assessment, with appropriate clinical examinations and typical symptom assessment. A negative test for nitrite/leukocytes may be considered to rule out UTI with sufficient certainty in patients with a low pretest probability. The detection of blood, leukocytes, and nitrite independently increases the likelihood of the presence of a UTI. The combination of the positive findings further increases the possibility of the diagnosis. The differential diagnosis for UTI includes consideration of other types of non-bacterial infection and the causes of recurrent UTI.

Uncomplicated Urinary Tract (uUTI) Infection Epidemiology


The epidemiology section provides insights about the historical and current Uncomplicated Urinary Tract Infection patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Uncomplicated Urinary Tract Infection epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

In the year 2021, Total Diagnosed Cases of Uncomplicated Urinary Tract Infection was 19,624 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted Uncomplicated Urinary Tract Infection epidemiology [segmented as Total Occurrence-specific cases of Uncomplicated Urinary Tract Infection, Total Diagnosed Cases of Uncomplicated Urinary Tract Infection, Total Age-specific Cases of Uncomplicated Urinary Tract Infection, Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection and Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Uncomplicated Urinary Tract Infection Epidemiology


The epidemiology segment also provides the Uncomplicated Urinary Tract Infection epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL-Views


To keep up with the current Uncomplicated Urinary Tract Infection patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Uncomplicated Urinary Tract Infection domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

  • The report covers the descriptive overview of Uncomplicated Urinary Tract Infection, explaining their causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Uncomplicated Urinary Tract Infection.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Occurrence-specific cases of Uncomplicated Urinary Tract Infection, Total Diagnosed Cases of Uncomplicated Urinary Tract Infection, Total Age-specific Cases of Uncomplicated Urinary Tract Infection, Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection and Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Uncomplicated Urinary Tract Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Uncomplicated Urinary Tract Infection
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Uncomplicated Urinary Tract Infection Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Uncomplicated Urinary Tract Infection Epidemiology Segmentation

Key Questions Answered


Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of Uncomplicated Urinary Tract Infection?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Uncomplicated Urinary Tract Infection patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Uncomplicated Urinary Tract Infection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about Uncomplicated Urinary Tract Infection?
  • Out of all 7MM countries, which country would have the highest occurrence-specific population of Uncomplicated Urinary Tract Infection during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Uncomplicated Urinary Tract Infection Disease market
  • To understand the future market competition in the Uncomplicated Urinary Tract Infection Disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Uncomplicated Urinary Tract Infection Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Uncomplicated Urinary Tract Infection Disease market
  • To understand the future market competition in the Uncomplicated Urinary Tract Infection Disease market

Table of Contents

1 Key Insights2 Report Introduction
3 Uncomplicated Urinary Tract Infection Market Overview at a Glance
3.1 Market Share (%) Distribution of Uncomplicated Urinary Tract Infection in 2019
3.2 Market Share (%) Distribution of Uncomplicated Urinary Tract Infection in 2032
4 Executive Summary of Uncomplicated Urinary Tract Infection (uUTI)
4.1 Key Events
5 Epidemiology and Market Methodology
6 Disease Background and Overview
6.1 Introduction
6.2 Types of UTI
6.3 Signs and Symptoms of Uncomplicated UTI
6.4 Risk Factors and Causes of Uncomplicated UTI
6.5 Pathogenesis of UTI
6.6 Complications of UTI
7 Diagnosis of Uncomplicated UTI
7.1 Diagnostic algorithm
7.2 Clinical Examination
7.3 Lab Tests
7.4 Imaging and other tests
7.4.1 Cystoscopy
7.4.2 Ureteroscopy
7.5 Differential diagnosis
8 Prevention of UTI
9 Diagnostic Guidelines
9.1.1 European Association of Urology (EAU) Urological Infections Diagnostic Guidelines
9.1.2 American Urological Association (AUA) Guidelines
9.1.3 Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)
10 Current Treatment Practices of Uncomplicated UTI
10.1 Treatment Algorithm
10.2 Antibiotic therapy
10.2.1 Uncomplicated cystitis
10.2.2 Uncomplicated pyelonephritis
10.2.3 Recurrent UTI
10.3 Antibiotic prophylaxis
11 Treatment Guidelines
11.1 American Urological Association (AUA) Guidelines
11.2 European Association of Urology (EAU) Urological Infections Treatment Guidelines
11.3 Comparison of AUA/CUA/SUFU and EAU Guidelines
11.4 National Institute for Health and Care Excellence (NICE) Guidelines
11.5 Infectious Diseases Society of America (IDSA), in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) Guidelines
11.6 Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)
11.7 NICE - Antimicrobial prescribing strategy for lower UTI (also called cystitis)
12 Epidemiology and Patient Population
12.1 Key Findings
12.2 Epidemiology of Uncomplicated Urinary Tract Infection (uUTI)
12.3 Epidemiology Scenario
12.3.1 Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection
12.3.2 Total Diagnosed Cases of Uncomplicated Urinary Tract Infection
12.3.3 Total Age-specific Cases of Uncomplicated Urinary Tract Infection
12.3.4 Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection
12.3.5 Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection
13 Appendix
13.1 Bibliography
13.2 Report Methodology
14 Publisher Capabilities15 Disclaimer16 About the Publisher
List of Tables
Table 1: Summary of uUTI Market and Epidemiology (2019-2032)
Table 2: Key classifications of UTI
Table 3: Cut-off values (colony forming units [CFU]/mL) for the diagnosis of UTI
Table 4: Diagnostic recommendations for Uncomplicated cystitis
Table 5: Diagnostic recommendations for Recurrent UTI
Table 6: Diagnostic recommendations for Uncomplicated pyelonephritis
Table 7: Diagnostic recommendations for recurrent UTI (rUTI)
Table 8: Suggested regimens for antimicrobial therapy in uncomplicated cystitis
Table 9: Suggested regimens for empirical oral antimicrobial therapy in uncomplicated pyelonephritis
Table 10: Suggested regimens for empirical parenteral antimicrobial therapy in uncomplicated
Table 11: Commonly used vaginal estrogen therapy
Table 12: Antibiotic prophylaxis dosing
Table 13: Treatment recommendations for recurrent UTI (rUTI)
Table 14: Treatment recommendations for Uncomplicated cystitis
Table 15: Treatment recommendations for Recurrent UTI
Table 16: Treatment recommendations for Uncomplicated pyelonephritis
Table 17: Treatment recommendations for Uncomplicated pyelonephritis
Table 18: Difference between AUA/CUA/SUFU and EAU Guidelines
Table 19: Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2019-2032)
Table 20: Total Diagnosed Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2019-2032)
Table 21: Total Age-specific Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2019-2032)
Table 22: Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2019-2032)
Table 23: Total Treated Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2019-2032)
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Symptoms of Uncomplicated UTI
Figure 3: Risk factors of UTI
Figure 4: Pathogenesis of UTI
Figure 5: Diagnostic algorithm for UTI
Figure 6: Treatment algorithm
Figure 7: Antimicrobial prescribing strategy
Figure 8: Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection in the 7MM (2019-2032)
Figure 9: Total Diagnosed Cases of Uncomplicated Urinary Tract Infection in the 7MM (2019-2032)
Figure 10: Total Age-specific Cases of Uncomplicated Urinary Tract Infection in the 7MM (2019-2032)
Figure 11: Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection in the 7MM (2019-2032)
Figure 12: Total Treated Cases (across the line) of Uncomplicated Urinary Tract Infection in the 7MM (2019-2032)